British Generic Manufacturers Association (BGMA)’s Post

By using #BiosimilarMedicines, healthcare professionals have access to a wider spectrum of treatment options and opportunities to change patient treatment pathways for the better. Take for example, biosimilars Infliximab and Adalimumab, used for the treatment of rheumatoid arthritis. Prior to these biosimilars being available, patients had to hit a higher threshold (only those with a more severe condition) and wait longer for access to treatment. Now thanks to biosimilar entry, those with moderate rheumatoid arthritis can also access treatment and improve their condition. Discover more by following #GlobalBiosimilarsWeek! #Biosimilars #RheumatoidArthritis #NHS

To view or add a comment, sign in

Explore topics